CD274 and neoplasm: A combination with an ICI (anti-PD-L1 antibody) had the most promising results; the results showed that the combinatorial treatment had the smallest tumor loads and highest percent survivals when compared with any of their previous syngeneic TNBC mouse model experiments [153].